Quidel Obtains Special 510(k) Clearance to Add Avian

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Quidel Obtains Special 510(k) Clearance to Add Avian Influenza A (H7N9) Virus Analytical Reactivity Information to the Package Inserts for All Three of Its Rapid Diagnostic Tests for Influenza

SAN DIEGO, CA--(Marketwired - Jul 15, 2013) - Quidel Corporation ( NASDAQ : QDEL ), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, received Special 510(k) clearance for an update to the Company's immunofluorescence-based Sofia® Influenza A+B FIA package insert to include analytical reactivity with an avian Influenza A (H7N9) strain, A/Anhui/1/2013, on July 5 th , 2013. Clearances of additional Special 510(k)s for its QuickVue® Influenza A+B and QuickVue Influenza visually read tests were also granted (June 28 th and July 5 th , respectively). The package inserts for all three products are being updated accordingly.

The novel influenza A (H7N9) virus is an avian influenza virus that has been shown to infect people in close contact with infected birds. In China, according to the CDC, approximately 130 people are known to have been infected with this virus and as of May 30, thirty-six (36) have died.(1) This virus is an avian influenza virus and is not readily human-to-human transmissible, but it is a high risk virus with pandemic potential. So far, no human cases have been identified outside of China.

The Sofia Influenza A+B FIA and both QuickVue influenza tests have been shown to detect the cultured A/Anhui/1/2013 virus analytically. However, the performance characteristics of these devices with clinical specimens from people that are positive for the A/Anhui/1/2013-like influenza A (H7N9) infection have not been established. The Sofia Influenza A+B FIA and the two QuickVue influenza kits can detect influenza A viruses, including this novel avian virus, but they cannot differentiate influenza A subtypes -- i.e., they cannot specifically identify this novel avian A (H7N9) or other avian or human influenza A subtypes.

Douglas Bryant, Quidel's president and chief executive officer, commented, "The first human infection with the novel avian influenza A (H7N9) was reported in China on April 1, 2013 -- only three and one half months ago. 1 The ability of the WHO, our U.S. regulatory and public health agencies, and our industry to react so quickly to dangerous, emergent viruses is an essential element of public health in the future, especially given the rapidly growing population and profound interconnectivity of the world's people made possible by rapid, comparatively inexpensive travel and commerce. Rapid tests, when used appropriately and correctly," Mr. Bryant added, "are useful tools in the effort to help diminish the spread of influenza. Quidel will continue to be alert to the advent of emergent influenza viruses with the intention of being poised to respond to important public health initiatives."

1 http://www.cdc.gov/flu/avianflu/h7n9-virus.htm , as of July 12, 2013.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Sofia® and AmpliVue® brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza , respiratory syncytial virus , Strep A, herpes, pregnancy, thyroid disease and fecal occult blood . Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com .

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, fluctuations in our operating results resulting from seasonality ; the timing of the onset, length and severity of cold and flu seasons ; government and media attention focused on influenza and the related potential impact on humans from novel influenza viruses ; adverse changes in competitive conditions in domestic and international markets ; the reimbursement system currently in place and future changes to that system ; changes in economic conditions in our domestic and international markets ; changes in sales levels as it relates to the absorption of our fixed costs ; lower than anticipated market penetration of our products ; the quantity of our product in our distributors' inventory or distribution channels and changes in the buying patterns of our distributors; our development of new technologies, products and markets; our development and protection of intellectual property; our reliance on a limited number of key distributors; our reliance on sales of our influenza diagnostics tests; our ability to manage our growth strategy, including our ability to integrate companies or technologies we have acquired or may acquire; intellectual property risks, including but not limited to, infringement litigation; limitations and covenants in our senior credit facility; that we may incur significant additional indebtedness; our need for additional funds to finance our operating needs; volatility and disruption in the global capital and credit markets; acceptance of our products among physicians and other healthcare providers; competition with other providers of POC diagnostic products; changes in government policies; adverse actions or delays in product reviews by the U.S. Food and Drug Administration (the "FDA"); compliance with other government regulations, such as safe working conditions, manufacturing practices, environmental protection, fire hazard and disposal of hazardous substances; third-party reimbursement policies; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance; the loss of key personnel; international risks, including but not limited to, compliance with product registration requirements, exposure to currency exchange fluctuations, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, political and economic instability, taxes, and diversion of lower priced international products into US markets; our failure to maintain adequate internal control over financial reporting; volatility in our stock price; dilution resulting from future sales of our equity; and provisions in our charter documents and Delaware law that might delay stockholder actions with respect to business combinations or the election of directors. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the Securities and Exchange Commission (SEC) from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Quidel Contact: Quidel Corporation Randy Steward Chief Financial Officer (858) 552-7931 Media and Investors Contact: Quidel Corporation Ruben Argueta (858) 646-8023 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 522

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 442

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 380

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 223

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 460

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 371

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 284

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Mallinckrodt's Potential Merger with Endo: Key Developments

Updated Category News Views 248

Mallinckrodt's Envisioned Merger with Endo Mallinckrodt plc, a leading global specialty pharmaceutical company, has made striking advancements in its proposed merger with Endo International plc. This significant event in the pharmaceutical industry not only showcases the evolving dynamics between two healthcare giants but also promises to create new opportunities for...

Continue Reading
FFBML Crowned as LendingTree's Top 10 Rated Mortgage Lender

Updated Category News Views 254

Customer Service Takes Center Stage After years of grappling with frustrating lenders, First Federal Bank Mortgage Lenders (FFBML) comes out swinging, earning a shiny new badge of honor—the Q3 2025 Top 10 Rated Lender from LendingTree for customer service in mortgage lending. This isn’t just some arbitrary title; it’s a testament to the grit and determination FFBML...

Continue Reading
Ecobat Successfully Transfers French Lead Operations to Campine

Updated Category News Views 219

Ecobat Finalizes Sale of French Lead Operations DALLAS — Ecobat, recognized as a leader in the battery recycling industry, has finalized the sale of its French lead operations to Campine NV. This transaction follows a strategic pathway outlined by the management to enhance focus on core initiatives within the battery recycling sector. Transaction Details The successful...

Continue Reading
RE/MAX Agents Maintain Dominance in Real Estate Performance

Updated Category News Views 431

RE/MAX Agents Excel in Real Estate Industry Performance In an exciting revelation, data from the 2025 RealTrends Verified rankings has confirmed that RE/MAX agents are once again leading the charge in productivity within the U.S. real estate market. These agents have outperformed their competitors at large brokerages with a striking ratio of 2:1, showcasing remarkable...

Continue Reading
Creo Engine Revolutionizes Blockchain Gaming with New Launches

Updated Category News Views 214

Transforming the Future of Gaming with Creo Engine Creo Engine is stepping up to change the game in the world of blockchain technology. With their innovative approaches, this rising company is bringing exciting solutions to the Web3 gaming community. Recently, they introduced the CreoPlay Bot Mini-app Beta Version, which is a game-changer in how players experience...

Continue Reading